Summit Therapeutics (SMMT) Assets Average (2016 - 2026)
Summit Therapeutics filings provide 12 years of Assets Average readings, the most recent being $699.5 million for Q1 2026.
- Quarterly Assets Average rose 70.74% to $699.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $699.5 million through Mar 2026, up 70.74% year-over-year, with the annual reading at $593.4 million for FY2025, 85.86% up from the prior year.
- Assets Average hit $699.5 million in Q1 2026 for Summit Therapeutics, up from $506.5 million in the prior quarter.
- Across five years, Assets Average topped out at $699.5 million in Q1 2026 and bottomed at $106.1 million in Q2 2022.
- Average Assets Average over 5 years is $323.8 million, with a median of $292.9 million recorded in 2025.
- The largest annual shift saw Assets Average soared 299.86% in 2023 before it tumbled 58.68% in 2024.
- Summit Therapeutics' Assets Average stood at $409.7 million in 2022, then crashed by 48.58% to $210.7 million in 2023, then surged by 122.68% to $469.2 million in 2024, then rose by 7.94% to $506.5 million in 2025, then skyrocketed by 38.12% to $699.5 million in 2026.
- Per Business Quant, the three most recent readings for SMMT's Assets Average are $699.5 million (Q1 2026), $506.5 million (Q4 2025), and $292.9 million (Q3 2025).